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Abstract
With an unprecedented mergers and acquisitions boom taking place in a pharmaceutical
industry suffering rocketing development cost and a stagnation in the number of new medicines
reaching the market, this dissertation provides insight on the extent to which this deal-making
trend has consequences on R&D productivity. This analysis is focused on 2009 Roche’s
acquisition of Genentech and shows the evolution of 6 key R&D metrics in a time frame that
includes the years preceding and following the transaction. It identifies the signals given in
terms of trends, which are instrumental to understand the transaction consequences on R&D
activity. Evidence has been found that suggests an overall positive impact. Nevertheless, it is
still necessary to continue tracking this particular case to assess if there is consistency in the
trends and identify which might be the key success factors. Moreover, the relationship between
the two companies involved and their R&D strategic direction is discussed.
Resumo
Face ao boom sem precedentes de aquisições e fusões numa indústria farmacêutica que
evidencia crescentes custos de desenvolvimento e uma estagnação do número de novos
medicamentos lançados no mercado, esta dissertação pretende estudar o efeito desta tendência
de realização de transações na produtividade da I&D. Esta análise centra-se na aquisição da
Genentech por parte da Roche em 2009, demonstrando a evolução de seis métricas chave num
período que inclui quer os anos anteriores quer os posteriores à transação. Os sinais dados em
termos de tendência são identificados e servem de instrumentos para a compreensão das
consequências da transação na atividade de I&D. Deste modo, encontrou-se evidência que
sugere um impacto geral positivo. No entanto, é necessária uma monitorização contínua deste
caso particular, de forma a avaliar a consistência das tendências e identificar quais poderão ser
os principais fatores de sucesso. Para além disso, é investigada a relação entre as duas empresas
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1. Introduction
I have found the pharmaceutical industry a fascinating subject. This industry was expected to
generate $1.23 trillion (USD) revenues in 2014, reaching an all-time record (The Economist
Intelligence Unit, 2014). Besides, among the largest companies in terms of revenues, drug
companies are those who have the highest average profit margin, even higher than banks
(Forbes, 2014). Indeed, this profitability, which is what matters at the end of the day, is linked
to the fact that this is a Research and Development (R&D) intensive industry. According to
Garnier (2008), discovering and developing a new compound requires at least 12 years and an
average investment that surpasses $1 billion (USD). This is higher than NASA’s budget for
sending a rocket to the moon.
Drug development costs are escalating exponentially, which constitutes the tip of the iceberg
of a series of serious trends that are threatening the stability of pharmaceutical companies.
Deloitte (2015) points out: “pharmaceutical companies around the globe continue to be buffeted
by blockbuster drug patent expirations, rapidly increasing competition from generics
manufacturers, and government and health care industry efforts to control costs — evidenced
by price controls, pro-generics policies, and patent challenges”. Hence, there is a turbulent
industry scenario, to which companies will need to face and adapt.
Moreover, a very strong M&A activity is a relevant characteristic that encompasses the
evolution of the industry. Several of the largest worldwide pharmaceutical companies such as
Merck, GlaxoSmithKline and Pfizer have been built as a succession of this kind of transactions,
as a way to strength their portfolio, gain high-potential molecules for their pipelines and
configure economies in their operations (The Economist, 2014). However, recently it is more
about focusing on what each company do best, to which M&A seems to be a popular tool to
strengthen the chosen areas to compete.
Considering this context, several authors have put the light on the M&A trend questioning if it
is effectively a mean to gain productivity (Munos, Lessons from 60 years of pharmaceutical
innovation, 2009), (LaMattina, 2011), (Tjandrawinata & Simanjuntak, 2012). This is, broadly
- 7 -
speaking, cost reduction and increase in new profitable drugs output. Thereupon, I decided to
treat the subject and generating some insight by addressing the following question: Which
behaviour display R&D performance of pharmaceutical companies following a merger or
acquisition deal? In order to accomplish this objective I decided to track the evolution of
relevant R&D performance indicators in order to infer and consequently generate pertinent
information.
As a mean to approach the question I have identified a particularly interesting acquisition
transaction. In 2009 Roche, today’s third largest pharmaceutical firm, reached an agreement
with Genentech, considered the most successful biotechnology company at the time, to buy at
$46.8 billion (USD) the remaining ownership of the company and putting an end to its
independent existence. In fact, Roche had hold a stock majority on Genentech since 1990.
Hence, this dissertation presents an analysis of several Roche Group’s relevant R&D indicators
evolution and identifies the impact of the transaction on these metrics, while provides context
information about the relationship management between both companies and explains the
company’s R&D strategic evolution. This acquisition case will serve as the instrument to
address the defined research question, aiming to provide understanding on whether M&A are a
suitable strategy to tackle the industry productivity problems, which demand an urgent solution




2.1 Pharmaceutical industry overview
The XX’s century pharmaceutical revolution had a massive impact in human kind´s quality of
life by eliminating diseases in developed countries, making feasible complex surgical
procedures and improving visibly patients’ life quality. It is estimated that pharmaceutical
innovation accounts for the 40% of the roughly 2-year increase in life expectancy during the
period between 1986 and 2000 (Lichtenberg F. R., 2005). Additionally, recent advances in
molecular genetics and molecular biology have the potential to address unmet pharmacological
needs, outlining a future for current drug R&D that had never been brighter in terms of human
impact (Rawlins, 2004).
Even though the industry is facing serious challenges that are changing the whole market
scenario, the likely future for the sector can be encouraging. Pharmaceutical sales are expected
to grow worldwide at an annual average rate of 6.9% between 2014 and 2018, surpassing the
5.2% overall healthcare spending growth rate forecasted for the period (The Economist
Intelligence Unit, 2014). Consequently, revenues for the industry will jump from 1.23 trillion
USD to 1.61 trillion in 2018. In particular, the global biotechnology sector is showing a larger
acceleration than the overall industry, totalizing sales of USD $288.7 billion in 2014 and a
CAGR of 10.8% during the last 5 years (IBIS, 2014).
Companies have different levels of importance in this tremendous USD $800 billion market
(Noor, 2014). In 2013, the top 10 companies by worldwide sales were respectively: Novartis,
Pfizer, Roche, Sanofi, Merck & Co, GlaxoSmithKline, Johnson & Johnson, AstraZeneca, Eli
Lilly and AbbVie (Noor, 2014). This publication additionally states that companies growing
the most are those with a strong portfolio in specialty medicines.
Indeed, the fact that Novartis took the first place in the market over Pfizer, which had hold this
privileged spot since 2012, indicates that the strategy of finding niches in the market is
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prevailing over other strategies such as the major and intense trend of M&A linked to Pfizer.
This trend questions seriously if economies of scale are the more reasonable answer to the
declining market power of pharmaceuticals (Looney, 2014). Moreover, while the overall global
sales of all pharmaceutical products grew 25% between 2008 and 2013, the specialty portfolio
doubled this rate (Noor, 2014).
Healthcare spending will undergo an acceleration, as it is expected to increase at higher
percentages than previous years at an average growth rate of 5.2% in the 2014-2018 period (The
Economist Intelligence Unit, 2014). This behaviour is mainly due to the high correlation of this
indicator with the overall economic conditions of countries. As it might be known, the global
economy is in a process of recovery. However, because of higher pressure from the part of
governments and healthcare institutions on reducing the costs and demonstrate value, the
spending is expected to grow at a lower rate than in the previous decade. (Deloitte, 2015)
2.2 Industry challenges
The future of pharmacotherapy should be brilliant, from the point of view that the current
technologies and advances should allow the industry to bring important discoveries to improve
life quality of people. However, the pharmaceutical sector risks of jeopardizing this potential if
they do not find a way to reduce the drug development cost (Rawlins, 2004). Even though the
pharmaceutical industry has been historically seen as an example of financial performance, in
recent years the companies of the sector have shown signs of weakness, raising questions about
the sector’s health. Indeed, from December 2000 to February 2008 the 15 main pharmaceutical
companies suffered an 850 billion reduction in shareholder value (Garnier, 2008).
Besides, taking into account the most respected studies in the field, the cost of drug
development has consistently risen over the years (Dickson & Gagnon, 2004), the study made
by DiMasi & Grabowski (2007) estimates that bringing a new molecular entity (NME) into the
market cost roughly USD $1.318 million. A NME (new molecular entity) is defined as “A New
Molecular Entity is an active ingredient that has never before been marketed in the United States
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in any form” (FDA, 2012) The latter number includes the allocation of failure costs of other
molecular entities as well as the opportunity cost, which impacts dramatically the figure due to
the lengthiness of the process. It was calculated that the process of discovering and development
a drug took on average 13.7 years to be completed (KMR Group, 2012). Due to modifications
on the drug approval process since the 1960s aiming at the improving drug safety and efficacy,
this cycle time has increased and therefore the cost of developing a new drug.
As a result of scientific and regulatory specificities in terms of frameworks, success
probabilities of each development phase and the lengthiness of the process, economic
uncertainty is always present, being a key variable of this risky business. The longer it takes to
develop a NME, the greater is the likelihood of an adverse event to occur or that a competitor
markets the discovery first, reducing this way the probable return on investment (Dickson &
Gagnon, 2004). The later adds to a competition scenario with market share erosion coming as
well from therapeutic competition and raising pressures from generics once patents are due
(Dickson & Gagnon, 2004). Nevertheless, the entry of biological products is softening this
erosion. From 2014 to 2020, it is calculated that USD $259 billion are at risk as a consequence
of patent expiration, however, only a 46% of it is actually expected to occur (EvaluatePharma,
2014).
Regarding regulation, the passage of the Hatch-Waxman Act in the United States during 1984
reduced barriers for generic competition in order to increase price competition in the
pharmaceutical market as a way to reduce pressure under healthcare budgets (Dickson &
Gagnon, 2004). Though generics are contributing to push prices down, the companies relying
on R&D are undergoing phenomenon, which increased rapidly its participation in the
prescription market of the United States from 50% in January 2007 to 68% in December 2007
(Murray, Berndt, & Cutler, 2008). Generics are expected to raise their global market share from
27% in 2012 to 36% in 2017 (IMS Institute for Healthcare Informatics, 2013).
Along with the generics trend, the industry is consistently failing to replace blockbuster drugs
with new ones. From every dollar lost due to declining products, companies had revenues of
0.77 in 2007 of products introduced within the previous 5 years, on account of industry’s
declining ability to regenerate their portfolios, this ration fell to USD 0.26 cents in 2012
(Goodman, 2008). Additionally, despite changes in patent law increasing patent protection
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time, the Effective Patent Life decreased due to the lengthy times required for clinical trial and
for obtaining regulatory approval, being estimated at 11.4 years by 1995 (Grabowski & Vernon,
2000). The Effective Patent Life (EPL) is defined as the number of years of market exclusivity
for a product once it has received marketing approval - EPL will always be less than the nominal
patent life because drug entities are patented long before they receive marketing approval -
(Dickson & Gagnon, 2004).
Several policy and demographic changes in the US are increasing even more the pressure on
pharmaceutical companies. The 2003 passage of the Medicare Prescription Drug, Improvement
and Modernization act gives federal government higher control on drug spending. As well,
States constraining healthcare expenditure, companies reducing employees’ health benefits, an
increasing number of Canadian and Mexican online pharmacies and a raising healthcare
demand for the growing elderly segment of population are phenomena challenging
pharmaceutical revenues. (Dickson & Gagnon, 2004)
Garnier (2008) highlights that the trends already mentioned are problems for the industry but
he considers that the decline in R&D productivity is the core of the difficult panorama, on which
Paul et al. (2010) agree. In addition to the rising costs, lower productivity in terms of new
products launched in the market complicates even more the pharmaceutical innovation scenario
and consequently the financial health of companies operating in the business. In fact, the
number of potential revenue-generating drugs over R&D expenditures ratio have gone down
sharply over the years (Paul, et al., 2010).
In spite of an impressive increase in pharmaceutical R&D investment during 1950 to 2008,
reaching USD 50 billion, the number of approved new drugs has remained almost unchanged.
This reflects that companies have been continuously innovating at a constant pace and may
simply mean this is the innovative capacity of the current R&D model (Munos, 2009).
However, the industry has shown positive signs in recent years. In 2014, 41 new drugs received
approval by the FDA, being the highest approval number in 18 years (Munos, Forbes, 2015).
As well, new drugs approvals in 2013 had a sales potential of US $24.4 billion, 43% higher
than the group of drugs approved in 2012, which, indeed, was the best year in drug approvals
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since 1997 in terms of NME and BLA (Biologics license applications) approvals
(EvaluatePharma, 2014).
Pharmaceutical companies need to routinely develop blockbuster drugs as fuel to value
creation, reason why the poor productivity of pharmaceutical R&D necessarily impacts
stakeholders’ pockets. Serious concerns are built up on the fact that in 2013 the projected value
of the 12 main pharmaceutical companies’ late-stage pipelines fell from 1,369 billion USD to
913 USD (Deloitte, 2013). Despite pharmaceutical sector have traditionally lead value creation
measured in annual return to shareholders over other industries; this situation is not anymore
the same. Between 2001 and 2007 this metric vanished even though the industry’s gross margin
and EBITDA margin had continuously grown for 20 years, reaching 78% and 32%,
respectively, in 2005. (Garnier, 2008).
It is clear that drug development is a risky, lengthy and expensive process. This added to the
fact that spending on pharmaceuticals have risen faster than other major costs of healthcare
system since the 1990s. DiMasi et al. (2003) explain why there are still more questions than
answers about how to address this scenario, a scenario where what is clear is that an efficient
use of resources is paramount (Dickson & Gagnon, 2004).
2.3 Strategic value of R&D operations
Few industries are as driven by R&D as the pharmaceutical industry where the development of
successful NME is the industry’s core activity. “The business model of Big Pharma is
straightforward. New products are discovered, developed, launched, and protected by various
patents. Initially the products benefit from monopolistic – or at least oligopolistic – pricing.
After 10 or 12 years, in general, patents expire and lower-priced generics come in, wiping out
the revenues of blockbuster drugs in a matter of weeks. R&D must continually replace older
products with new ones to stop the revenue base from shrinking” (Garnier, 2008).
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The resource-based view of the firm (Wernerfelt, 1984) emphasizes that companies need to
balance the exploitation of existing resources and the development of new ones, in order to
keep a constant renewal and have an optimal growth in the long run. This core competence,
translated in terms of R&D is essential in the pharmaceutical industry. The creation of an
innovative drug is the engine that moves a whole cycle in which societal value, revenues and
cash flows ultimately refuel R&D the creation of another innovative new drug (Dickson &
Gagnon, 2004).
Thus, R&D operations are a critical component of strategy execution (Bremser & Barsky,
Utilizing the balance score card for R&D performance measurement, 2004) and are a
shareholder and customer value creating function (Pearson, Nixon, & Kerssens-van Drongelen,
2000). Therefore, R&D objectives need to be in line with corporate strategy (Bremser &
Barsky, Utilizing the balance score card for R&D performance measurement, 2004). From this
formulation, the essential objective of the R&D department is to create, sustain and exploit in
and efficient and efficient way the technological knowledge base of the company (Kerssens-
van Drongelen & Bilderbeek, 1999). In the pharmaceutical industry in particular, R&D plays
the central role (Scherer, 2000), which is explained by the fact that R&D patents generation and
exclusive rights constitute a legal rewarding system directly enchained with financial
performance (Hyunju, 2014).
Regarding investment, it was observed that roughly one third of the information taken into
account to justify the decisions was non-financial (Ernst & Young, 1998). Moreover, Kelm et
al. (1995) examined the impact of R&D announcements on the stock value of companies
concluding that in R&D intensive industries, information about R&D progress is a key
determinant of changes of firms’ value.
Bremser & Barsky (2004) stress that efficiency, effectiveness and timeliness in the innovation
process is crucial to strategy implementation. Particularly, positive financial effects on
pharmaceutical companies derived from improvements in the R&D process have been assessed
by DiMasi (2002); finding that a 25% reduction in drug development phases time, would bring
an estimated USD $129 million decrease in drug development cost. The study finds that by
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upgrading preclinical success rate from 21.5% to 33%, companies could cut average cost
development by US $221 million.
Highlighting the importance of the latter, Paul et al. (2010) reiterate that improvements in
processes are not only compatible with good science but together will definitely result in
brighter yields on pharmaceutical investments, more R&D projects, and, at the end of the day,
more therapies to patients (DiMasi J. A., The Value of Improving the Productivity of the Drug
Development Process, 2002).
2.4 Drug development
The drug development process starts when a molecule having an interesting pharmacological
and market potential is identified. Thereupon, the preclinical stage has begun, consisting of a
series of tests aiming to assess the toxicity and the pharmacological potential in laboratory
animals using in vitro and then in vivo techniques (Dickson & Gagnon, 2004). Rawlins (2004)
explains that preclinical safety studies under the current development model involve a battery
of tests for the new chemical entity (NCE), such as single-and-repeat-dose and special toxicity
tests, a study of biological processes effects and a pharmacokinetic analysis (Rawlins, 2004). If
the compound by the end of this set of tests is considered to have potential, an Investigational
New Drug Application is filed to the FDA explaining the results already obtained (Dickson &
Gagnon, 2004), results that eventually will be used to discern the direction human testing should
take (FDA, 1999).
Subsequently, if the FDA does not classify the application as ‘hold’, Phase I clinical trials could
begin within 30 days. Phase I studies have as main objective to determine in healthy volunteers
the adequate dosing range and the toxicity of the molecule (Dickson & Gagnon, 2004). Having
a compound which has flown throughout Phase I successfully, it will continue to Phase II in
order to “indicate whether, and at what dose, a new drug’s anticipated therapeutic benefits are
observed in patients; and to provide some preliminary indication of its safety in humans”
(Rawlins, 2004). If the NCE is still considered promising it would advance to Phase III, in
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which wider samples of patients having the target disease are taken with the main purpose of
demonstrating efficacy at verify which are the right doses (Rawlins, 2004). DiMasi, Hanse &
Grabowski (2003) comment that the number of patients involved in Phase III trials can reach
the thousands. The next step, if the molecule has gone successfully throughout Phase III, is to
file a New Drug Application (NDA) along with the safety and efficacy proofs (Dickson &
Gagnon, 2004). In case it is a biological compound, a biological license application (BLA)
approval by the FDA would be required to launch the product to the market (DiMasi, Hansen,
& Grabowski, The price of innovation new estiamtes of drug development costs, 2003).
There is not a unique of total development time estimate, however, authors agree on the fact
that it is a lengthy process (Dickson & Gagnon, 2004); (DiMasi, Hansen, & Grabowski, The
price of innovation new estiamtes of drug development costs, 2003); (Rawlins, 2004).
According to Dickson & Gagnon (2004), the average time devoted to preclinical and clinical
trials is 8.5 years (Based in FDA data), The Pharmaceutical Research and Manufacturers of
America (2014) reported that the R&D process can take between 10 and 15 years, DiMasi
(1995) presents that the average time since the compound synthesis to the FDA approval was
12.8 years in the 1990s (DiMasi J. A., Trends in Drug Development Costs, Times and Risks,
1995) and 13.7 years is the cycle time including the drug discovery period. (KMR Group, 2012).
It is interesting to point out that this time has been increasing over the years, mainly in the
clinical trial part of the process, finding as explanation to this phenomenon several factors such
as more regulation, the increased trial samples, higher difficulty in recruiting people to
participate in the tests and the more complex nature of diseases being targeted (Dickson &
Gagnon, 2004). In fact, the average number of people involved in clinical stage trials has more
than double in the US (DiMasi, Hansen, & Grabowski, The price of innovation new estiamtes
of drug development costs, 2003).
According to Rawlins (2004), drug regulatory authorities in the United States and in Europe
have made substantial contributions to make sure the new chemical entity meet the criteria of
safety and efficacy, reason why nowadays failures of pharmaceutical quality are rare. However,
the author presents a critique in which a review of regulatory exigencies is claimed, since those
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might in many cases be unnecessary or oversized due to lack of inclusion of evidence-base and
value for money principles in the regulatory definition. This rationale is linked to the increasing
payers demand for higher drug value for money (Dickson & Gagnon, 2004).
Additionally, it is a main characteristic of drug development that only a reduced percentage of
the molecules running the process accomplish to being a marketed drug. Considering that most
of the main companies aim to have 2 to 5 launches every year and that roughly 9 NME entering
clinical trials are needed per year in order to have a single new drug launch, the required number
of molecules entering clinical pipeline are numbers very rarely achieved (Paul, et al., 2010). In
fact, on the basis of a study conducted with date ranging from 1983 to 1994 the overall clinical
success rate was estimated in 21.5% (DiMasi, Hansen, & Grabowski, The price of innovation
new estiamtes of drug development costs, 2003).
Discovering a new drug can be like a needle in a haystack and there is not an only pathway for
drug research. Indeed, in some cases it is due to serendipity (FDA, 1999). Moreover, to illustrate
everything behind a single new drug, the organization Pharmaceutical Research and
Manufacturers of America estimated that only 1 in 5,000 NCE entering preclinical stage
manage to finally reach the pharmacy shelves (FDA, 1999). This notion of the proportion of
NCE entering the R&D pipeline that survive the whole process, being finally approved by the
correspondent organism is the most definitive measure of risk in the pharmaceutical industry
(Dickson & Gagnon, 2004).
2.5 Cost of drug development
During the pharmaceutical innovation process, high fixed costs are incurred and a lengthy time
period is spent before the investments yield any return (DiMasi J. A., The Value of Improving
the Productivity of the Drug Development Process, 2002). As it might be pointed out, there is
great concern among academics, companies, journalists and governments about the steady
raising in average cost per NME over the years. Dickson & Gagnon (2004) compared 7 studies
carried out during a 20-year period estimating the cost of developing a new NME on the basis
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of 2000 USD and the condition of having used similar methodologies. These studies allocate
the failures costs to the NME that actually received approval and the opportunity costs using as
limit of the time frame the point of marketing approval. The discussion showed the rapidly
increasing costs in pharmaceutical development, which according to the authors analysis is
mainly explained by the costs associated to the animal studies and the clinical trials.
In (DiMasi J. A., Hansen, Grabowski, & Lasagna, 1991) the out-of-pocket cost of developing
a NME was estimated at USD 114 million, resulting in a 231 million USD capitalized average
cost using a 9% discount rate in 1987 dollars. In an update of the latter study, DiMasi and
colleagues (2003) estimated the capitalized average cost of NME development in USD 802
million in 2000 dollars, using an 11% discount rate. The average cost increase between 1991
and 2003 can be expressed in an annual growth rate of 7.4% above inflation (DiMasi, Hansen,
& Grabowski, The price of innovation new estiamtes of drug development costs, 2003).
Moreover, in a more recent study, the estimates found in 2005 dollars were USD 1241 million
for biopharmaceuticals and USD 1318 million for pharmaceuticals (DiMasi & Grabowski, The
Cost of Biophramaceutilca R&D: Is Biotech Different?, 2007).
The development cost per NME has steadily risen over decades. Using 12 different studies over
a 48-year time period, it was found that this cost has been increasing at a 13.4% annual rate
since the 1950s (Munos, 2009). Dickson & Gagnon (2004) note that pharmaceuticals
representatives claim that rising costs of medicines are explained by the increasing expenditures
to speed up drugs development, increasing regulation and investments to improve research
accuracy.
Additionally, capitalized costs are severely impacted by the lengthy development time.
Considering the 2003 DiMasi’s study, the cost due to the time value of money account for a
half of the total capitalized estimate of US $802 million (DiMasi, Hansen, & Grabowski, The
price of innovation new estiamtes of drug development costs, 2003). The development cost is
dependent on the length of each stage in the process, the success rate of each phase and the
phase in which each failure occur (DiMasi J. A., The Value of Improving the Productivity of
the Drug Development Process, 2002). The timing in drug development might be the key to
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address the challenges most pharmaceutical companies are going through as it is suggested in
Paul et al. (2010). The author explains that there are too many resources invested in the final
stages of NCEs with low pharmaceutical probability of success and not very high revenue
potential.
Quite a lot has been discussed about enormous drug development costs and medicines prices,
however, it is interesting as well to assess the value new drugs create. It was estimated that a
nondrug expenditure reduction of USD 72.22 for an USD 18 expenditures increase due to new
drugs using 1996 data (Lichtenberg F. R., 2001). Hence, pharmaceutical added value is
observable in terms of non-drug decreased expenditures and in patients’ life quality, even
though it is unclear the yield of investments in R&D and prescription drug payments vis-à-vis
the accomplished benefits (Dickson & Gagnon, 2004).
2.6 Productivity definition in R&D
Productivity can be defined in the literature simply as the average R&D cost per NME reaching
the marketplace. This is the object of particular preoccupation considering facts such us the
expanding investment in pharmaceutical research and development, which in fact went from
USD 2 billion in 1980 to USD 43 billion in 2006 while the output of the whole system measured
in new approved drugs remained roughly flat (Garnier, 2008).
More precisely, R&D can be defined as the ratio between value created and the value invested
to generate a new drug (Paul, et al., 2010); (BCG, 2011); (Accenture, 2007). In a paper issued
by the Boston Consulting Group (2011), the value created can be measured as the number of
NME and BLA attaining the market and the value invested as the economic value of resources
used as input. On the other hand, in (Paul, et al., 2010) the numerator is explained as the medical
and commercial value created by the new drug and the denominator as the investments done to
generate the compound. Moreover, acknowledging that “the goal of a highly productive R&D
system is to efficiently translate inputs into the most desired and valuable outputs” (Paul, et al.,
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2010), the author develops his definition including efficiency and effectiveness components of
pharmaceutical drug R&D process resulting in a formula as follows:
∝ . ( ) .
(Paul, et al., 2010)
Thus, in the denominator there is work in process (WIP), probability of success (p(TS)), value
(V)-understood in terms of health and economic benefits. In  the denominator the components
are development cycle time (CT) and cost (C). It is relevant to mention that the majority of
components in this equation are interrelated, meaning that they can depend directly or indirectly
on others (Paul, et al., 2010).
In a 2007 publication, Accenture exposes a methodology measurement approach developed
jointly with the Centre for Medicines Research International Ltd. (CMR) aiming to improve the
traditional measurement, they turn it more value-oriented and more holistic by incorporating
the return on investment concept and implicitly success rates. This measure can be used whether
for the whole industry or a specific company and is defined as the ratio between the first 5-year
revenue of a new drug and the average cost of developing a NCE (Accenture, 2007).
In addition, an interesting finding to stress the importance of addressing productivity decline is
the fact that the average exclusivity time due to patents decreased from 5.5 years in 1999 to
roughly 4, being the lowest known ever (Garnier, 2008). However, there are good news as well,
leading R&D organizations are able to run NME through their pipelines 4 years faster than
other pharmaceuticals and have success rates toughly 4 times higher (Accenture, 2007).
2.7 R&D Performance Measurement
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“Performance measurement can be defined as the acquisition and analysis of information about
the actual attainment of company objectives and plans, and about factors that may influence
this attainment” (Kerssens-van Drongelen & Bilderbeek, 1999). Performance measurement
(PM) systems are necessary for strategy implementation, in such a way they reflect the current
levels and changes in financial and nonfinancial indicators (Bremser & Barsky, Utilizing the
balance score card for R&D performance measurement, 2004). In a study conducted with
literature ranging between 1956 and 1995, performance measurement systems in R&D
integrating several types of qualitative and quantitative metrics were found to be the most
effective, even though entailing higher complexity and costs in their use (Werner & Souder,
1997) .
A popular framework to address R&D performance measurement is the Stage-Gate approach
(2007) which puts the focus on linking advances in the technical stages to sales and finally to
customer expectations, as a way to promote a more rapid launch and a market-oriented process
(Bremser & Barsky, Utilizing the balance score card for R&D performance measurement,
2004). The model consists in five stages and five gates. The stages are initial screen, develop
the business case, development, test and validation, and, ultimately, production and full launch.
The gates are points where decision as to go backwards, put an end to the project, or continue
to the following stage are made (Bremser & Barsky, Utilizing the balance score card for R&D
performance measurement, 2004). Particularly, the Stage-gate approach has the characteristic
of being more suitable than techniques such as Discounted Cash Flows and Payback that are
more pertinent for later phases of the development process (Nixon, 1998).
Another model used to conceive performance measurement systems is the Technology Value
Pyramid (TVP) (Tipping, 1995). The TVP defines hierarchical categories of managerial factors
regarding the R&D process, having in the top of the pyramid value creation as the ultimate
objective, organizational strategy in terms of products portfolio in the middle and R&D
competencies and processes as the pyramid foundations. According to this approach, the TVP
critical metrics are those able to reflect value creation since these are growth predictors
(Bremser & Barsky, Utilizing the balance score card for R&D performance measurement,
2004).
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The Economic Value Added (EVATM) has been equally used as a performance measurement
system. It is a financial approach focused exclusively in the outputs, specifically in the wealth
generation for shareholders, which in addition entails a compensation system based on
delegation and empowerment, reason why it promotes the accountable division of the
organization (Pearson, Nixon, & Kerssens-van Drongelen, 2000). However, there is a major
interest in not only financial-oriented PM systems but broader ones such as The Balance
Scorecard (Kaplan & Norton, 1992).
Roughly speaking, The Balance Scorecard (BSC) is a managerial tool created in order to
integrate in a sole PM system operational and financial metrics considering that financial results
are the consequence of operational performance. The BSC requires companies to develop a
series of goals aligned with corporate strategy as to translate them into performance metrics
aiming to fulfil key company objectives (Kaplan & Norton, 1992). The whole BSC managerial
approach involves practices that might not be suitable for all companies, however, firms could
implement a non-formal BSC but rather make use of some useful key concepts of the system
(Bremser & Barsky, Utilizing the balance score card for R&D performance measurement,
2004).
Bremser & Barsky (2004) formulated an integrated R&D performance system combining the
Stage-Gate approach with The Balanced Scorecard, aiming to present a framework that targets
activities and strategic objectives at the same time. By introducing a 6th stage named Product
Support and Program Review the authors create a refinement allowing a better integration with
the BSC system. The integrated system has as main purpose to provide a clearer connection of
technical processes with sales and marketing under a customer-oriented perspective, which in
theory should result in products going through the R&D pipeline more rapidly and the
fulfilment of customer needs.
Building on (Werner & Souder, 1997) findings on the fact that performance measurements
integrating qualitative and quantitative metrics are the most effective, Bremser & Barsky (2004)
observe that the Stage-Cooper framework (Cooper, 1993) reflects the latter idea. Moreover, the
BSC manages to connect shareholder value creation to managerial decision, and additionally
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solves the problem of tying together data of the past to strategic objectives to be accomplished
in the future (Bremser & Barsky, Utilizing the balance score card for R&D performance
measurement, 2004).
Defining the appropriate metrics and PM system might result quite polemic, nevertheless, in
(Pearson, Nixon, & Kerssens-van Drongelen, 2000) it is concluded that there is no unique
methodology or framework which could be entirely suitable for each particular circumstance in
the R&D environment. Moreover, the authors point out that R&D measurement have to match
the R&D particular organizational characteristics.
2.8 Performance indicators in R&D
There is an increasing importance on having reliable metrics due to the need to demonstrate the
pertinence of R&D investments, quantify the economic value of R&D for the company and
provide information about the level of efficiency in the use of such resources (Schwartz, Miller,
Daniel, & Fusfeld, 2011). As well, companies are increasingly aiming to align business
operations and resource management towards corporate strategy and create a managerial culture
driven by performance measurement (Accenture, 2007).
In order to identify the most used performance metrics in R&D, the Goldense Group Inc. (GGI,
2005) conducted a study in 2004, in which data was collected from 202 North American,
European and Asian companies present in diverse industrial sectors, on which respondents were
asked to select from a 75-metrcis lists which of them they used. The study reports that the 5
most used metrics has remained the same compared to a previous study carried 6 years before
(1998) by the same institution.
Considering the previous top-10 ranking of the most used R&D metrics published by GGI and
presented as well in (Donnelly & Fink, A P&L for R&D, 2000) it raises the question about the
usefulness of such metrics to align the R&D function towards corporate strategy (Bremser &
Barsky, Utilizing the balance score card for R&D performance measurement, 2004).  Moreover,
the concern that roughly 40% of new products do not accomplish the expected results (Donnelly
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& Fink, A P&L for R&D, 2000) exists. Thus, Bremser & Barsky (2004) present an illustrated
application of the BSC to the R&D function defining suitable strategic indicators for each of
the 4 perspectives (Kaplan & Norton, 1992) and the likely metrics to be used in order to
accomplish strategic objectives. Such metrics might be in line with several indicators and could
change over time considering the strategic learning loop approach.
Table 1. Most used R&D metrics in industry rank
1. R&D spending as a percentage of sales
2. Total patents filed/pending/awarded
3. Total R&D headcount
4. Number of products/projects in active development
5. First year sales of new products
6. Percentage of resources/Investment dedicated to new projects
7. Current-year & sales due to new products released in the past N years
8. First year profits of new products
9. Percentage of resources/investment dedicated to sustaining existing
products
10. Number of products released
Source: (GGI, 2005)
Metrics ranking number 1 and 2 in GGI study (2005) are required for financing reporting and
mandatory by regulation, respectively. Even so, some interesting trends seem to have emerged.
The metrics ranking 4th and 5th might indeed be in line to promote corporate strategic objectives
fulfillment (Bremser & Barsky, Utilizing the balance score card for R&D performance
measurement, 2004). The study suggests there are an important amount of measures being tried
in industrial R&D in order to determine which are more useful, and among which it will emerge
the new metrics portfolio used for a large proportion of companies in the future (GGI, 2005).
Additionally the study reveals that companies more than doubled the number of metrics in use,
and, very interestingly, it appears that several companies are measuring R&D investment yield
by creating ROI-similar ratios. Even though, such quite positive progresses in R&D
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measurement, it is recalled for the establishment of healthcare outcome metrics as mortality and
hospitalizations reductions of new drug introductions (Paul, et al., 2010).
2.9 Common measures limitations
Despite positive advances towards better metrics to assess R&D performance (GGI, 2005), it
is criticized that companies traditionally have put the focus on merely financial metrics which
do not play a good role as innovation drivers (Pearson, Nixon, & Kerssens-van Drongelen,
2000); (Kaplan & Norton, 1992). Furthermore, studies have stressed the fact that companies do
not have a balanced set of metrics for the different organizational levels, i.e. individual,
department and company level (Kerssens-van Drongelen & Bilderbeek, 1999); and
additionally, companies lack of R&D metrics linking strategically operations to key financial
indicators (Donnelly & Fink, A P&L for R&D, 2000).
When measuring R&D performance the difficulty of commensurability, which is the property
that makes comparable a set of results of a specific metric exists, due to the fact that innovation
is by definition something new. However, it does not mean that comparisons cannot be made
but this must be considered on designing performance measurement (Fagerberg, Mowery, &
Nelson, 2005). In addition, Fagerberg et. al (2005) consider the existence of a problem in
addressing innovation with a focus in processes, considering that the very concept of innovation
is defined at the level of ideas, learning and knowledge production or even in terms of
competences. Still, aiming to be more productive in R&D activities experts argue that
accounting systems need to allow the measurement of individual projects or products
contribution to companies’ profits and revenues (Donnelly & Fink, 2000).
2.10 M&A in the Pharmaceutical Industry
M&A is a vehicle to trade resources such as technology, knowledge, capabilities, brands and
markets that in other fashion would not be feasible (Wernerfelt, 1984). In pharmaceutical
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industry, an increasing M&A trend arose during the first decade of XXI century (Tjandrawinata
& Simanjuntak, 2012), which strengthened in the days of the financial crisis (The Economist,
2014). Pfizer, Roche, Sanofi-Aventis, Astrazeneca, Meck, Eli Lilly, Takeda and Teva are in the
list of companies that have gone through M&A transactions (Tjandrawinata & Simanjuntak,
2012). This phenomenon is considered to have been driven by NME pipeline scarcity (Munos,
2009), rising R&D costs (DiMasi, Hansen, & Grabowski, The price of innovation new estiamtes
of drug development costs, 2003), patent expiration and consequently revenue drop and a thirst
for new drug blockbusters (Tjandrawinata & Simanjuntak, 2012).
In a study conducted by (Munos, 2009) using data of 24 acquisitions and 6 mergers with at least
10-year information pre and post the transaction, the author concludes that only in small
companies there is a modest but significant increment in NME output. On the other hand, M&A
in larger companies do not appear to create or destroy any value, even though, mergers effect
in half of big pharmaceutical companies cases was positive and in the remaining half negative
in terms of NME output. Considering acquisition in larger companies, 70% had a negative effect
on drug production and 30% increased NME output by 41%. Moreover, Munos (2009) found
that the number of companies explain significantly the overall NME output of the industry,
indicating that the only fashion to increase industry productivity is by increasing the number of
companies, which is in fact the opposite direction to M&A trend.
John LaMattina, former president of Pfizer global R&D, argues that M&A impact on
organizations that have gone throughout the integration process has been devastating. Initially
these strategic movements are attractive as they lower costs and companies emerge, likely, with
created synergies (Danzon, Epstein, & Nicholson, 2007). LaMattina contends that R&D clearly
suffers in the post-transaction in terms of current pipeline, procedures and IT platforms
integration, resulting in a lengthy phase that at least takes 9 months, early-stage R&D
slowdown, an overall loss of momentum and, even more, motivation suppression on employees.
As it has been already mentioned, the pharmaceutical industry have created NME at a roughly
flat rate in the last 60 years, which in fact puts a question mark on the current R&D model and
mean that M&A have had a undetectable effect on pharmaceutical R&D NME production;
moreover, the fact that NME output tend to be higher in companies not particularly relying in
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M&A might point out M&A is not an effective strategy in order to foster R&D and raise lack
of productivity (Munos, 2009).
At this point in pharmaceutical industry evolution when post M&A transaction spending in
R&D is being cut, authors stress as well the major need for new developments to treat
conditions and diseases such as Alzheimer, Diabetes and drug-resistant infections (LaMattina,
2011). Nevertheless, this cost cuts do not constitute a major improvement and it might mean
there is a serious structural problem, which needs to be addressed (Munos, 2009). Even so, it is
unlikely that the era of mega M&A will soon come to an end (LaMattina, 2011).
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3. Methodology
As a way to provide understanding about the behaviour that R&D performance displays in
pharmaceutical companies following a merger or acquisition deal, I have decided to use the
recent acquisition transaction by Roche over Genentech and analyse the evolution of relevant
R&D performance indicators, considering they provide a quantitative approach to track the
R&D productivity evolution in terms of effectiveness and efficiency. I decided to assess the
evolution of R&D performance using such metrics inasmuch they have the potential to provide
clearer and more accurate findings. R&D indicators allow improving the R&D operations
efficiency and are a tool to justify funding given to projects (Germeraad, 2003).
The Roche-Genentech transaction in March 2009 is among the largest transactions ever on the
pharmaceutical history. This deal is particularly interesting due to the fact that Roche, the third
largest pharmaceutical firm in the world, decided to finally integrate Genentech, an American
company, on which Roche had hold a majority stake since 1990 but that had existed mainly
independent. With this deal Roche acquired the blockbusters Avastin and Mabthera (Rituxan)
as well as the development pipeline of the most successful biotechnology company at the time.
It is considered that by this transaction Roche reaffirms its will of not getting into the generic
or consumer business and strengths its commitment to innovation (Shantikumar, 2009).
Among the rank of the 10 most used R&D indicators in the industry (GGI, 2005), 5 of them
were studied in this dissertation. Specifically, the data analysed correspond to the
pharmaceutical division, which reports Genentech results as part of the whole division numbers
since the 1999 takeover that gave Roche control over the American Biotechnology company.
Besides, 1 of the indicators was assessed from 2 complementary perspectives in order to get a
better understanding, for a total of 6 annual indicators, which are: R&D spending as percentage
of sales, number of new products released, first year sales of new products as percentage of
total sales, current year sales due to products released in the past 3 years, number of
development projects and number of new medical entities in development.
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This set of performance indicators was selected taking into account that they are meaningful,
straightforward and particularly intuitive, reasons why they are likely the preferred indicators
to assess R&D operations according to the 2005 study conducted by the consulting firm
Goldense Group Inc. In that study a significant sample of companies from North America,
Europe and Asia was surveyed, as outlined in the literature review. The top five metrics are
used by more of the half of the respondent companies and the remaining by at least a 36% of
them (GGI, 2005). As well, that study considered only corporate metrics and project-level
indicators since they provide overall measures of the R&D activity, which contribute
significantly to understand the company performance as a whole.
Not all of these metrics were used for the purposes of this analysis. Those used in this
dissertation were chosen considering the aim of creating a group of metrics that could be enough
to assess R&D from the input, output and process perspective (Muller, Välikangas, & Merlyn,
2005), avoiding to include too many at a point that it could result misleading or unfocused. The
availability of information was an important criteria to do the selection since in many cases the
data required was not consistently reported or insufficient. As well, the suitability of the
indicators for this dissertation was evaluated taking into account to what extend they were
predictors of strategic objectives accomplishment. In the subsequent paragraphs the importance
of each of the chosen metrics and their linkage to main company objectives is explained and
justified in detail.
The R&D spending as percentage of sales indicator or R&D intensity is the most used indicator
due to the fact that it is required by reporting normativity. It is relevant taking into account that
there is a positive correlation between this indicator and financial performance (Kotabe, 1990)
and competitiveness (Gee, 1981).On the other hand, the number of new products released
indicator is linked to the internal business perspective of the BSC according to the example
application given by Bremser & Barsky (2004) and they are a key aspect for companies to
reinvent themselves and adapt to changing market conditions (Schoonhoven, Eisenhardt, & &
Lyman, 1990). Regarding the latter indicator, for the sake of this dissertation new products are
considered only NME that reach the market for the first time under any commercial name.
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The percentage from first year sales of new products indicator show the effectiveness of R&D
function and is linked to the customer perspective in the BSC illustration given in Bremser &
Barsky (2004) and to the financial perspective according to the example provided in Kerssens-
van Drongelen & Cooke (1997). Additionally, the current year sales due to products released
in the past 3 year’s indicator provide similar assessment as the previously mentioned indicator
but with a longer perspective on time considering product’s life evolution. It was selected a 3
years perspective to track the previous indicator taking into account it was the timeframe used
to assess new product development success in Cooper, R. & Kleinschmidt (2007). In order to
attempt to compute these metrics it was necessary to build a database where it the launch year
of each product was identified and included yearly sales data per product.
In R&D intensive companies such pharmaceuticals, the richness of the pipeline, which can be
measured in terms of the number of projects in active development, is particularly important
taking into account the fact that bringing new medical indications to the market is the truly core
business of the industry, particularly in firms such as Roche that have chosen to stick to a
genuine innovative strategy due to the fact that it is a metric that indicates the potential of future
cash flows. In fact, investors react positively to R&D innovation stage announcements of
companies with a technological focus (Kelm, Narayan, & Pinches, 1995). Hence, the number
of projects in development indicator, which includes additional indications of already launched
molecules as well as first indications, is a metric that show company capability to innovate. In
particular, the number of NME in a pharmaceutical pipeline is a key factor to analyse
considering that this compound are those with the largest potential of turning into blockbuster
drugs.
The data was extracted from the annual reports of Roche ranging between 1999 and 2014 and
depending on the indicator the data had to be processed in order to obtain the final metric to be
used. Each indicator was plotted as a mean to obtain trend signs that were confirmed with the
statistical Chow test using a suitable software tool. In such fancy it was possible to obtain a
measure of the indicators behaviour and infer what the transaction impact on Roche’s R&D
activities was in absolute and trend terms, i.e., what was had before and what was obtained after
the 2009 deal. Besides, by using percentages different effects as acquisitions and exchange rates
changes are considered to be suppressed.
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4. Results
4.1 The Roche Group
Roche is a life sciences group based in Basel (Switzerland) with a worldwide presence. Today
it is the main biotechnology company in the world and their biopharmaceuticals account for
roughly a half of the Group Sales (Roche Holding Ltd, 2007). As well, Roche has developed a
strong commitment to the field of personalized healthcare, what they consider a mean to bring
tailored products for specific populations and provide more cost-effective solutions (Hoffmann-
La Roche Ltd, 2010). After several spin-offs to concentrate in their strongest business areas,
the group has exclusively 2 divisions, Roche Pharmaceuticals and Roche Diagnostics, among
which the pharmaceutical division is the largest one and the main growth driver (Roche Holding
Ltd, 2008).
In terms of strategy, the Group considers essential finding market niches (F. Hoffmann-La
Roche Ltd, 2012) and aligning both divisions by promoting collaboration between them in order
to create a successful competitive advantage. All this strategy aims to translate their operations
into personalized healthcare solutions that might offer economic value. As well, the company
decided in 2009 to decentralize their R&D projects structure by creating 5 Disease Biology
Areas (DBAs) - Oncology, Viral Diseases, Inflammation, Metabolic Diseases and Central
Nervous System - constituting an effort to allow independent decision making and enhance
their pipeline value (Roche Holding Ltd, 2009). Moreover, the growth strategy has relied both
in organic growth and in a systematic series of acquisitions and product transactions. Their
innovation model involves a global collaborative network with about 150 partners, including
external biotech companies, universities and research organizations around the world
(Hoffmann-La Roche Ltd, 2010).
4.2 The Roche-Genentech relationship
Until 2008 Genentech has been a Roche’s majority-owned subsidiary along with Chugai, the
Japanese company that went through a Roche takeover in 2002. Roche’s relationship with
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Genentech dates form the early 1980 when Roche established a cooperation agreement with the
pioneering biotechnology company (Roche Holding Ltd, 2007). Subsequently, in September
1990 the Group acquired a majority stake of approximately 60% in the California-based biotech
company (Roche Holding Ltd, 2006). In 1999 Genentech and Roche defined a licensing
agreement, allowing Roche to sell Genentech products in markets different to the US (Roche
Holding Ltd, 2009). Up to that point Genentech had operated mostly independently (Roche
Holding Ltd, 2008).
On the 21st of July 2008 Roche announced its proposal to acquire Genentech remaining stake
not owned by the Group. However on the 13th of August of the same year Genentech rejected
the acquisition. The final deal was achieved on March the 12th 2009; it was reached with a
successful offer of $ 95 (USD) per share. In consequence Genentech became a wholly owned
subsidiary of the group in March the 26th 2009. The transaction amount was of 52.7 billion
Swiss francs -$47.0 billion (USD) - (Hoffmann-La Roche Ltd, 2010).
The Roche Group understood the acquisition as an opportunity to reach a higher level of
integration and consequently achieve an improved operational efficiency in their
pharmaceutical division. (Roche Holding Ltd, 2009). Once the deal was reached, Roche
released a series of restructuring actions costing 2.4 billion Swiss francs in 2009 that included
the closure of manufacturing and R&D facilities as well as the consolidation of administrative
functions (Hoffmann-La Roche Ltd, 2010). These restructuring activities had been almost
completed by the end of 2010, reaching a total cost of 3.3 billion Swiss francs.
4.3 Post-transaction scenario
Following the Genentech integration, the Group decided to preserve the independence of
Genentech Research and Early Development innovation center re-named gRED that together
with pRED constitute the main innovation base of the pharmaceutical company. The latter, is
an attempt to preserve the successful innovation culture of the original biotechnology company.
Both innovations centers have separate budgets, autonomy to develop their own network of
external partners and autonomy to manage their innovation activities (Hoffmann-La Roche Ltd,
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2010). However, Genentech late-stage development activities were integrated into Roche’s
pharmaceutical division. “This integration included prioritizing projects within the shared
portfolio and eliminating activities that are either duplicated or no longer required, notably in
the administration function” (Hoffmann-La Roche Ltd, 2010).
“Today, Roche is the world’s largest biotechnology company, with 14 biological products on
the market. These biologics constitute 65% of our product portfolio, compared with an industry
average of just 16%” (F. Hoffmann-La Roche Ltd, 2012). Additionally, the Group reported that
Roche is the leading company in oncology medicines and that they have reached a “unique”
position to turn Personalized Healthcare into a reality (F. Hoffmann-La Roche Ltd, 2012).
4.4 R&D intensity
This metric is defined as the ratio between sales and R&D expenditures over one year. As we
can observe in Figure 1 the indicator reached a peak in 2009, year on which the integration was
carried out. We can affirm there is a trend breakpoint on 2009 considering the results of the
Regression Stability Test (Chow test).  Hence, there is a positive trend component of the data
series from 2005 up to 2009 and a decreasing trend afterwards until the last reported year. On
the other hand, in absolute terms, the mean between the two considered periods show a slight
decrease superior to one percentage point, dropping from 20.71% to 21.58%.
Figure 1. R&D intensity indicator evolution
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In 2010 the company began to undergo tough market conditions due to the financial crisis and
to experience stronger pricing pressures coming from governments, which required reducing
their healthcare budgets. As a mean to cope with this scenario, Roche launched the “Operational
Excellence” program in November 2010 in order to strengthen Group’s productivity
(Hoffmann-La Roche Ltd, 2011). This program mainly included a significant workforce
reduction and had an application period that extended until 2013. This restructuring program
very likely impacted R&D intensity evolution by pushing it downwards.
This post-acquisition decreasing trend might be interpreted as positive from the cost-efficiency
point of view, meaning that R&D operations are sustained demanding a lower percentage of
revenues, which is a short term advantage. However, there is evidence that R&D spending is
one of the 4 key success factor in new product development since it was found to be a predictor
of new product sales (Cooper & Kleinschmidt, 2007), reason why in a long term perspective it
will likely have a negative impact on the company results.
4.5 Number of new products
The number of new products indicator accounts for the number of first-time launches of
products containing as active compound a NME and not new indications of already launched
molecules or approvals in additional countries of molecules already being marketed. In this data
set no relevant trend component was identified. However, there is a significant difference
between the 1999-2008 period and the 2009-2014 period. In the period ranging from 1999 to
2008 the average number of new products launched was 1.5 whereas between 2009 and 2014
the average was 1.17, which corresponds to a 22% decrease.
From the point of view that discovering and developing a new pharmaceutical products is such
a lengthy process and a massive effort on which thousands of compounds are rejected to finally
launch a product to the market, it is unlike that this metric will show a strong trend component
and it might need more time to show a trend change if indeed it existed. Besides it is discrete
indicator and only can be tracked in terms of entire values. As well, the global NME entities
output is considered a structural problem of the pharmaceutical industry (Munos, Lessons from
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60 years of pharmaceutical innovation, 2009) and might need more substantial actions.
Nevertheless, it is worth it to highlight the fact that in the three last years, from 2012 to 2014,
it has been consistently 2 launches per year.
Figure 2. Number of new products indicator evolution
4.6 New products first year sales as percentage of total sales
Regarding the sales percentages due to new products metric, from 2005 to 2008 it evolved with
a negative trend, subsequently, in the 2009-2014 period the indicator has shown a slight recover
but still not reaches previous levels of performance. This is confirmed by the Chow test, which
demonstrates that there is a breakpoint between both data sets, meaning each one follows
different trend parameters. Nonetheless the trend reversion, the average of this metric dropped
from a 2.91% average corresponding to the first period to a weak 0.65% in the more recent
period.
As the previously analysed indicator the new products first year sales as percentage of total
sales metric might take several years to certainly show the impact of actions taken over time.
Still, the final years of a medicine development process are crucial and taking into account that
Genentech and Roche late-stage development activities underwent a fusion, it is considered that
there is enough time to create a significant impact on this performance indicator. It is worth
mentioning that during 2009 and 2010 there was no product launches, reason why this indicator
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dropped to zero in those years. As well, it is possible to infer that 2009 and 2011 launches were
not particularly successful in their first year of sales.
Figure 3. Sales percentage due to new products indicator evolution
4.7 Current year sales due to products released in the past 3 years
Figure 4. Sales of products released in the last 3 years indicator evolution
This indicator displays a similar behaviour to the sales percentage due to new products metric,
which indeed is expected considering both of them are linked. From 2006 up to 2012 there is
exponential negative evolution of the indicator, which is followed by trend reversion during
2013 and 2014. The average for the first period is of 2089 million Swiss francs and 1755 million
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Swiss francs for the two last reported years, corresponding to a 42% drop. However, it results
particularly interesting due to the fact that this indicator has surprised in 2014 with the highest
value in the last seven years. Moreover, as it is possible to observe in Figure 4 the trend
breakpoint appeared in 2013, several years after the transaction was completed, which is a
lagged effect due to the fact that the very metric conception involves three years data
backwards.
4.8 Number of projects in development
With regard to the number of active development projects of the Swiss group, a strong positive
trend component in the 2000-2008 period was identified. Following this period, the indicator
stagnated and the trend from 2009 to 2014 could be assessed as null or negligible. On the other
hand, in absolute terms, the 2000-2008 period shows an average of 88 projects in development
while the 2009-2014 period average is considerably superior with a 113 mean.
Figure 5. Number of projects in development indicator evolution
4.9 Number of NME in development
This metric displays a positive trend component in the period ranging between 2006 and 2011
as is possible to observe in Figure 6. In the subsequent years it has been identified a negative
trend component, which means there is a significant breakpoint in the time series and it is not
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stable. In spite of this trend change, the average NME in the development pipeline is superior
in the latter period. During the 2000-2011 period the average of NME in the pipeline was 61
and 68.for the three last years.
Figure 6. Number of NME in development indicator evolution
As it has been already mentioned, the impact of measures taken could start to have a significant
impact several years afterward they had been implemented. The fact that since 2012 it has been
observed a weakening trend is a matter of concern due to it might be signalling the truly
innovative capacity of Roche Group is in decline.
4.10 Roche findings comparison with overall industry trends
By analysing the data reported for pharmaceutical sales and R&D spending over the years, the
worldwide overall industry had a declining R&D intensity in the years ranging from 2008 to
2011, when reached its lowest point. In the subsequent years, starting on 2012 and continuing
until 2014, the last reported year, the indicator have shown a positive trend (EvaluatePharma,
2014). By comparing this to Roche, it is possible to affirm that Roche is not in line with this
overall industry behaviour since Roche’s R&D expenditures to sales ratio only started to suffer
a decline in 2010 and it has not displayed a recovery pattern so far.
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In regard to the total number of new biological and pharmacological compounds reaching the
market per year, by analysing the amount FDA approvals it is possible to observe a positive
and consistent increasing trend in the 2011-2014 period, which is good news for the
pharmaceutical industry (Thomson Reuters, 2015). In particular, in 2014 the industry reached
an all-time high in the last decade. However, when comparing this to Roche’s performance to
this overall industry numbers, it appears that the number of new approvals for the company is
mostly flat and do not present a consistent increasing trend.
Furthermore, according to EvaluateFarma 2015 report, the revenue generating capacity of NME
in the US during the 5-year post launch period has been displaying a positive recovery trend
from 2012 onwards, which indeed match the results observed in the new products first year
sales as percentage of total sales metric and the current year sales due to products released in
the last 3 years metric. On the other hand, with respect to pipeline volumes in the industry, it
has been reported a decline (Deloitte, 2015) (Thomson Reuters, 2015) at the time that the NPV
of development projects has raised (EvaluatePharma, 2014) (EvaluatePharma, 2015), which
might signal that pharmaceuticals are tending to focus its resources in the most promising
compounds. When comparing the latest trend to Roche’s findings, it is observed that there is
not a match of the particular company trend and the overall industry trend, due to the number
of Roche development projects has showed a recovery trend in recent years, which is the
opposite of the overall industry behaviour.
4.11 Roche pharmaceuticals current scenario
Roche currently has a strong commitment in targeting the specialty pharmaceutical market
considering they are the largest pharmaceutical segments and among those that are growing at
a higher rate. As well, the company has specifically defined as key growth drivers the oncology
and autoimmune disease therapeutic areas, or in general terms, the hospital and biologics
segments in which the company is already leader (F. Hoffmann-La Roche Ltd, 2013) (F.
Hoffmann-La Roche Ltd, 2013).
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Roche continue to rely on acquisitions to foster its growth, complement their R&D programs
and strengthen their pipeline. Notably, in 2014 Roche’s Pharmaceutical Division acquired a
100% stake in InterMune by 8.8 billion Swiss Francs, which gives Roche access to a medicine
that threats idiopathic pulmonary fibrosis. Despite the M&A deals, Roche Pharmaceuticals is
still struggling to show strong revenue growth rates in the last years.
The company highlights its efforts to improve their R&D efficiency as the cost of developing a
NME continue to rise for them, which they identify is due in part the need of screening more
molecule candidates before selecting which is a plausible drug candidate and the fact that higher
regulatory requirements impose more complex procedures. The company understands that by
reducing the time it takes to turn a compound into a medicine they are containing R&D
expenditures and among those efforts the company is promoting the use of new technologies,
innovation in trial designs and fostering pharmaceutical collaboration as a mean to access and
share knowledge externally (F. Hoffmann-La Roche Ltd, 2014).
Alliances seems to be key to face today’s industry challenges. There is a pharmaceutical
collaboration network called TransCelerate BioPharma which allow Roche to collaborate with
other 17 companies to achieve the objective of simplify clinical trial operations. Moreover, the
company holds an area named Roche Partnering (RP), which is responsible for managing
everything that has to do with collaboration and M&A opportunities. In 2014, RP was managing
about 190 external partnerships worldwide. In fact, 35% of Roche’s pharmaceutical pipeline is
externally sourced and roughly a third of the divisional sales come from products resulting from
a partnering agreement (F. Hoffmann-La Roche Ltd, 2015).
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5. Conclusions
There is evidence that allow us to infer that there are positive signals in the post fusion scenario
of Genentech on Roche regarding the metrics analysed. A decreasing trend of R&D spending
has been identified that can be interpreted as positive from the point of view of cost efficiency.
In terms of new product launches it has not been identified any particularly significant trend,
however it is an optimistic fact that consistently it has been two product launches in the last
three years. Besides, there is consistent evidence of a recovery of new product sales as
percentage of sales metric as well as the sales due to products launched in the previous three
years indicator, which show there is a signal of improvement it terms of new product success.
Regarding the number of projects in active development and the number of NME in
development, which reflect the innovation capacity of Roche’s pharmaceutical division, there
is evidence of not very encouraging signals after the integration. Nevertheless, when assessing
this kind of companies, more important than the volume of a pharmaceutical pipeline, what is
key is the capacity of turning this pipeline into blockbuster drugs and generate value for
shareholders and the society by providing healthcare solutions. Thus, this might be an indicator
of cost-effectiveness efforts, by really concentrating the available resources into the more
promising projects.
The evolution of the metrics assessed signal a decreasing productivity in the years preceding
the integration, mainly considering the rising R&D expenditures and the decline of sales of new
products metrics and new product launches. Hence, it is very likely that the decision of reaching
an acquisition agreement with Genentech was a mean to tackle this important issue.
Nevertheless the recent positive evolution of the R&D indicators tracked in this dissertation, it
is needed to show consistency in the improvement trends and not only reach previous levels of
sales and R&D productivity but outpace them.
For the purpose of this dissertation it is considered more relevant the trends detected than the
averages corresponding to the data sets regrouped under each of those trend lines. The latter
because trends highlight the directions on which productivity indicators are evolving and are
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considered a forecast of the future, providing much more rich information. Still, as can be
observed in Table 2, despite the trend changes detected, in most of the metrics analysed it was
observed that they do not present a slope large enough as to create the corresponding expected
difference in absolute values.
Table 2. Results Summary
Indicator Trend change Average change
R&D intensity Negative Positive
Number of new products Null Negative
Percentage of new products sales Positive Negative
Percentage of products released in the last 3 years Positive Negative
Number of projects in development Negative Positive
Number of NME in development Negative Positive
It has been possible to infer that Roche and Genentech fusion affected R&D performance due
to the fact that there are significant trend changes that match this event as it has been described
in the results chapter, suggesting that the actions taken had relevant consequences on Roche
Pharmaceuticals R&D productivity. Yet, there were circumstances as the world financial crisis,
pressures on governments to reduce their healthcare budgets, the generalized productivity
decline in the industry and the recurrent Roche’s intern productivity efforts among others that
very likely contribute to explain this dissertation findings.
When comparing this dissertation findings to industry reports, it is possible to assess that
revenue generation metrics of new products in fact match the overall global industry trend. On
the other hand, the R&D intensity metric correspond only partially to pharmaceutical industry
evolution of this indicator and regarding the remaining set of metrics tracked in this dissertation,
it is observed no correspondence to the main industry indicators. As well, as mentioned in the
results chapter, Roche has continued relying on acquisitions to grow on top of organic company
growth, which indeed is not a particular condition of this company. The number of deals in the
pharmaceutical industry has remained more or less stable form 2010 onwards, while the
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transactions value across the industry almost doubled in 2014 after a 2-year period of not
particularly high numbers (EvaluatePharma, 2015). According to The Economist Intelligence
Unit (2014) the main drivers of this consolidation activity in the business are the increasing
demand of generic drugs and the drop in blockbuster sales caused by due patents in the largest
industry players.
Improving R&D productivity in pharmaceutical industry remain a subject of major concern as
governments’ pressures to provide higher value rise, the number of NMEs reaching the market
stagnates and development cost continue climbing. Roche in particular, the third largest
company in the industry, a firm associated with cutting-edge innovation and considered
successful, recognizes this challenge and has relied on acquisitions, collaborations and
productivity initiatives at company level in order to tackle this major issue, continue growing
and show the performance its stakeholders expect. Yet, the question whether this strategy will
work or a deep structural revolution in the drug industry on the way things are managed is truly
needed remains on the table.
Only time will confirm the evidence it has been found in this dissertation as the M&A trend
continue in the industry and productivity problems are still unsolved. If Roche climbs or
declines in the Pharmaceutical industry as a world class player, if the years when Roche’s
pharmaceutical division outperformed the market are ready to return, if it is a company where
truly innovation is developed or a specialized investment fund, are as well questions waiting
for answers.
5.1 Limitations and future research
The results of this dissertation only apply to the Roche-Genentech case, since only this
particular transaction was analysed, thus, a more complete study should be done in each of the
metrics involving a richer number of deals as to obtain a generic result and provide further
evidence about the casual effects of M&A transactions on pharmaceutical R&D productivity.
As well, in spite of it is possible to link the studied metrics to generate a performance assessment
with regard to efficiency, performance measurement should move to metrics showing more
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directly the relationship of R&D efforts with bottom line results as Donnelly and Fink (2000)
suggest.
In what regard to Roche acquisition over Genentech, it might be still early to conclude on the
definitive effects of the Roche-Genentech integration since only 5 years have passed following
the transaction. Hence, it is necessary to continue tracking this case as to assess if there is
consistency in the trends that were identified and if this was the case, study which were the
factors that might be instrumental to accomplish a successful integration and achieve positive
results in R&D terms. Moreover, despite of the signals detected, there is a diversity of factors
on which company results depend such us overall industry trends, business cycles and random
causes, among others, that could have influenced the results founded. As well, the fact that
company results are consolidated and reported in Swiss francs might have introduced a margin
of error in the monetary figures analysed.
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Appendices
Appendix 1. Illustrated application of the Balance Scorecard to the R&D department
Source: (Bremser & Barsky, 2004)
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Appendix 2. Example of a balanced scorecard for a R&D organization
Source: (Kerssens-van Drongelen & Cooke, 1997)
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